BlackRock Fund Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

BlackRock Fund Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$78.7M	Buy	2,100,902 +173,565	+9%	+$7.27M	0.01%	1382
2016 Q3	$131M	Buy	1,927,337 +56,455	+3%	+$3.98M	0.03%	875
2016 Q2	$104M	Buy	1,870,882 +32,506	+2%	+$2.05M	0.02%	946
2016 Q1	$115M	Buy	1,838,376 +112,252	+7%	+$7.46M	0.03%	837
2015 Q4	$162M	Sell	1,726,124 -177,587	-9%	-$16.5M	0.04%	605
2015 Q3	$153M	Buy	1,903,711 +121,946	+7%	+$13.5M	0.04%	604
2015 Q2	$214M	Buy	1,781,765 +89,153	+5%	+$10.7M	0.05%	429
2015 Q1	$177M	Buy	1,692,612 +237,280	+16%	+$24M	0.04%	572
2014 Q4	$141M	Sell	1,455,332 -10,963	-0.7%	-$1.02M	0.03%	674
2014 Q3	$115M	Buy	1,466,295 +58,472	+4%	+$3.77M	0.03%	735
2014 Q2	$88.9M	Sell	1,407,823 -902,180	-39%	-$53.6M	0.03%	971
2014 Q1	$155M	Buy	2,310,003 +96,481	+4%	+$7.47M	0.05%	519
2013 Q4	$142M	Sell	2,213,522 -35,480	-2%	-$2.12M	0.04%	571
2013 Q3	$144M	Buy	2,249,002 +337,517	+18%	+$16.8M	0.05%	490
2013 Q2	$59.3M	Buy	+1,911,485	New	+$50.9M	0.02%	1078

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BlackRock Fund Advisors's ALNY Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 9% in Q4 2016, buying an estimated $7.27M and bringing the position to 2,100,902 shares worth $78.7M. The position accounts for 0.01% of the portfolio, ranked #1382.

BlackRock Fund Advisors first reported a position in ALNY in Q2 2013 and has held it in 15 quarters since. The position peaked at $214M in Q2 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

BlackRock Fund Advisors held 2,100,902 shares of Alnylam Pharmaceuticals worth $78.7M as of Q4 2016.
BlackRock Fund Advisors bought 173,565 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $7.27M.
Alnylam Pharmaceuticals made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1382 holding.
BlackRock Fund Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Alnylam Pharmaceuticals position peaked at $214M in Q2 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.